lotebex 250 mikrograma otopina za injekcije
edicta pharm d.o.o., klaićeva 62, zagreb - palonosetronum - otopina za injekciju - 250 mikrograma - urbroj: 1 ml otopine sadrži 50 mikrograma palonozetrona (u obliku palonozetronklorida)
rubraca
pharmaand gmbh - rucaparib camsylate - neoplazme jajnika - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca prikazan kao monoterapija za liječenje odraslih bolesnika s платиночувствительный recidiva kvalitetan epitela jajnika, jajovoda ili primarni перитонеальным raka, koji se u odgovor (potpuno ili djelomično) na bazi platine kemoterapije.
imfinzi
astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
isentress 400 mg/1 tableta filmom obložena tableta
merck sharp & dohme bh d.o.o. - raltegravira - filmom obložena tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 mg raltegravira (u obliku kalijumraltegravira)
endoxan 50 mg/1 tableta obložena tableta
co.medprom d.o.o. - ciklofosfamid - obložena tableta - 50 mg/1 tableta - 1 obložena tableta sadrži: 50 mg ciklofosfamida, anhidrovanog (53,5 mg ciklofosfamid, monohidrata)
endoxan 200 mg/1 boca prašak za rastvor za injekciju
co.medprom d.o.o. - ciklofosfamid - prašak za rastvor za injekciju - 200 mg/1 boca - 1 bočica sadrži: 200 mg ciklofosfamida, anhidrovanog (213,8 mg ciklofosfamid monohidrata)
endoxan 500 mg/1 boca prašak za rastvor za injekciju
co.medprom d.o.o. - ciklofosfamid - prašak za rastvor za injekciju - 500 mg/1 boca - 1 bočica sadrži: 500 mg ciklofosfamida, anhidrovanog (534,5 mg ciklofosfamid monohidrata)
endoxan 1000 mg/1 bočica prašak za rastvor za injekciju
co.medprom d.o.o. - ciklofosfamid - prašak za rastvor za injekciju - 1000 mg/1 bočica - 1 bočica sadrži: 1 g ciklofosfamida, anhidrovanog (1069 mg ciklofosfamid monohidrata)
blitzima (▼) 10 mg/1 ml koncentrat za otopinu za infuziju
oktal pharma d.o.o. sarajevo - rituksimab - koncentrat za otopinu za infuziju - 10 mg/1 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 10 mg rituksimaba
daurismo
pfizer europe ma eeig - glasdegib maleate - leukemija, mieloidna, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.